Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

 

 

On March 16, 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson published the long-term data of the third phase of the DISCOVER-2a study. The trial showed that TREMFYA® (guselkumab), a selective IL-23 inhibitor, lead to skin clearance and joint symptom relief for up to two years in patients with active psoriatic arthritis (PsA).

Read the complete press release to learn more about the data collected from this long-term Phase-3 trial. 

 

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

 

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK